A Narrative Review of Stem Cell‐Derived Exosomes for Diabetic Nephropathy
TL;DR
Comparisons between different exosome types indicate that MSCs‐derived exosomes (MSC‐Exos) may offer superior therapeutic benefits, while clinical trials are ongoing to evaluate the safety and efficacy of stem cell‐derived exosomes in DN patients.
Abstract
Diabetic nephropathy (DN) remains a major cause of end‐stage kidney disease. Stem cell‐derived exosomes have emerged as a promising therapeutic strategy due to their ability to deliver bioactive molecules to damaged tissues. This narrative review, conducted in accordance with PRISMA guidelines, aims to evaluate the therapeutic potential of exosomes derived from various stem cell sources, including mesenchymal stem cells (MSCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs), in the context of DN. A comprehensive literature search was performed using relevant databases (e.g., PubMed, Web of Science, Scopus) to identify preclinical and clinical studies investigating the effects of stem cell‐derived exosomes on DN. The identified studies were assessed for quality and methodological rigor. Priority was given to high‐impact studies and those with robust experimental evidence. The selected literature was synthesized thematically to provide a coherent overview of the current state of research on exosome‐based therapies for DN, highlighting current findings, and future directions. Results from preclinical studies suggest that exosomes derived from different stem cell sources can exert reno‐protective effects, including reducing inflammation, fibrosis, and oxidative stress. However, comparisons between different exosome types indicate that MSCs‐derived exosomes (MSC‐Exos) may offer superior therapeutic benefits. While clinical trials are ongoing to evaluate the safety and efficacy of stem cell‐derived exosomes in DN patients, further research is needed to optimize exosome production, delivery, and therapeutic efficacy.